S Boeck

Summary

Affiliation: University of Munich
Country: Germany

Publications

  1. ncbi KRAS mutation status is not predictive for objective response to anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer
    Stefan Boeck
    Department of Internal Medicine III and Comprehensive Cancer Center, Klinikum Grosshadern, Ludwig Maximilians University of Munich, Marchioninistr 15, 81377, Munich, Germany
    J Gastroenterol 48:544-8. 2013
  2. ncbi EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104
    S Boeck
    Department of Internal Medicine III and Comprehensive Cancer Center, Klinikum Grosshadern, Ludwig Maximilians University of Munich, Marchioninistr 15, Munich D 81377, Germany
    Br J Cancer 108:469-76. 2013
  3. ncbi Glucose and lipid metabolism in patients with advanced pancreatic cancer receiving palliative chemotherapy
    Katharina Zeiss
    Department of Internal Medicine III and Comprehensive Cancer Center, Klinikum Grosshadern, Ludwig Maximilians University of Munich, Marchioninistr 15, D 81377 Munich, Germany
    Anticancer Res 33:287-92. 2013
  4. ncbi Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer
    Volker Heinemann
    Department of Internal Medicine III, Klinikum Grosshadern, University of Munich, Germany
    BMC Cancer 8:82. 2008
  5. ncbi Prognostic and therapeutic significance of carbohydrate antigen 19-9 as tumor marker in patients with pancreatic cancer
    Stefan Boeck
    Department of Internal Medicine III, Klinikum Grosshadern, Ludwig Maximilians University of Munich, Munich, Germany
    Oncology 70:255-64. 2006
  6. ncbi Kinetics of dendritic cell chimerism and T cell chimerism in allogeneic hematopoietic stem cell recipients
    S Boeck
    Department of Internal Medicine III, Klinikum Grosshadern, Ludwig Maximilians University of Munich, Munich, Germany
    Bone Marrow Transplant 37:57-64. 2006
  7. ncbi The role of second-line chemotherapy after gemcitabine failure in patients with advanced pancreatic cancer
    Stefan Boeck
    Ludwig Maximilians University of Munich, Department of Internal Medicine III, Klinikum Grosshadern, Marchioninistrasse 15, D 81377 Munich, Germany
    Future Oncol 4:41-50. 2008
  8. ncbi [A 19-year-old patient with acute promyelocytic leukemia and knee swelling]
    S Bock
    Medizinische Klinik und Poliklinik III, Klinikum der Universitat Munchen Grosshadern, Munchen, Germany
    Internist (Berl) 47:629-32. 2006
  9. ncbi Cisplatin-based chemotherapy for pulmonary metastasized germ cell tumors of the testis--be aware of acute respiratory distress syndrome
    Stefan Boeck
    Department of Internal Medicine III, Klinikum Grosshadern, Ludwig Maximilians University of Munich, Germany
    Onkologie 32:125-8. 2009
  10. ncbi Severe lung and skin toxicity during treatment with gemcitabine and erlotinib for metastatic pancreatic cancer
    Stefan Boeck
    Department of Internal Medicine III, Klinikum Grosshadern, Ludwig Maximilians University of Munich, Germany
    Anticancer Drugs 18:1109-11. 2007

Detail Information

Publications33

  1. ncbi KRAS mutation status is not predictive for objective response to anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer
    Stefan Boeck
    Department of Internal Medicine III and Comprehensive Cancer Center, Klinikum Grosshadern, Ludwig Maximilians University of Munich, Marchioninistr 15, 81377, Munich, Germany
    J Gastroenterol 48:544-8. 2013
    ..It has not yet been defined if KRAS has a prognostic value or is a predictive biomarker for the efficacy of erlotinib in advanced pancreatic cancer (PC)...
  2. ncbi EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104
    S Boeck
    Department of Internal Medicine III and Comprehensive Cancer Center, Klinikum Grosshadern, Ludwig Maximilians University of Munich, Marchioninistr 15, Munich D 81377, Germany
    Br J Cancer 108:469-76. 2013
    ..We aimed to identify molecular epidermal growth factor receptor (EGFR) tissue biomarkers in pancreatic cancer (PC) patients treated with the anti-EGFR agent erlotinib within the phase 3 randomised AIO-PK0104 study...
  3. ncbi Glucose and lipid metabolism in patients with advanced pancreatic cancer receiving palliative chemotherapy
    Katharina Zeiss
    Department of Internal Medicine III and Comprehensive Cancer Center, Klinikum Grosshadern, Ludwig Maximilians University of Munich, Marchioninistr 15, D 81377 Munich, Germany
    Anticancer Res 33:287-92. 2013
    ..The role of diabetes mellitus (DM) in the pathogenesis of pancreatic cancer (PC) and its prognostic role on patients with advanced disease remain undefined...
  4. ncbi Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer
    Volker Heinemann
    Department of Internal Medicine III, Klinikum Grosshadern, University of Munich, Germany
    BMC Cancer 8:82. 2008
    ..Single-agent gemcitabine (GEM) is a standard treatment for advanced and metastatic pancreatic cancer. This study examines the question whether GEM-based combination chemotherapy can further improve treatment efficacy...
  5. ncbi Prognostic and therapeutic significance of carbohydrate antigen 19-9 as tumor marker in patients with pancreatic cancer
    Stefan Boeck
    Department of Internal Medicine III, Klinikum Grosshadern, Ludwig Maximilians University of Munich, Munich, Germany
    Oncology 70:255-64. 2006
    ..It still remains to be defined whether the CA 19-9 response is a more reliable method for evaluating treatment efficacy compared to conventional imaging...
  6. ncbi Kinetics of dendritic cell chimerism and T cell chimerism in allogeneic hematopoietic stem cell recipients
    S Boeck
    Department of Internal Medicine III, Klinikum Grosshadern, Ludwig Maximilians University of Munich, Munich, Germany
    Bone Marrow Transplant 37:57-64. 2006
    ..Our results thus demonstrate a fast and stable CDC in DC1, DC2 and T cells after AHCT that continuously increases over time in nearly all patients...
  7. ncbi The role of second-line chemotherapy after gemcitabine failure in patients with advanced pancreatic cancer
    Stefan Boeck
    Ludwig Maximilians University of Munich, Department of Internal Medicine III, Klinikum Grosshadern, Marchioninistrasse 15, D 81377 Munich, Germany
    Future Oncol 4:41-50. 2008
    ..However, results from large randomized Phase III trials are still lacking and therefore no evidence-based treatment recommendation can be given for patients with advanced pancreatic cancer after failure of first-line gemcitabine...
  8. ncbi [A 19-year-old patient with acute promyelocytic leukemia and knee swelling]
    S Bock
    Medizinische Klinik und Poliklinik III, Klinikum der Universitat Munchen Grosshadern, Munchen, Germany
    Internist (Berl) 47:629-32. 2006
    ....
  9. ncbi Cisplatin-based chemotherapy for pulmonary metastasized germ cell tumors of the testis--be aware of acute respiratory distress syndrome
    Stefan Boeck
    Department of Internal Medicine III, Klinikum Grosshadern, Ludwig Maximilians University of Munich, Germany
    Onkologie 32:125-8. 2009
    ..In patients with lung metastases and a high tumor load, an association between induction chemotherapy and the development of a 'tumorassociated' acute respiratory distress syndrome (ARDS) has been hypothesized...
  10. ncbi Severe lung and skin toxicity during treatment with gemcitabine and erlotinib for metastatic pancreatic cancer
    Stefan Boeck
    Department of Internal Medicine III, Klinikum Grosshadern, Ludwig Maximilians University of Munich, Germany
    Anticancer Drugs 18:1109-11. 2007
    ..Thus, pulmonary side effects should be regarded carefully in pancreatic cancer patients receiving palliative therapy with gemcitabine and erlotinib...
  11. ncbi [Molecular-based treatment concepts in advanced pancreatic cancer]
    S Boeck
    Medizinische Klinik und Poliklinik III,
    Dtsch Med Wochenschr 132:818-22. 2007
  12. ncbi Assessing prognosis in metastatic pancreatic cancer by the serum tumor marker CA 19-9: pretreatment levels or kinetics during chemotherapy?
    Stefan Boeck
    Department of Internal Medicine III, Klinikum Grosshadern, Ludwig Maximilians University of Munich, Germany
    Onkologie 30:39-42. 2007
    ..CA 19-9 pretreatment levels as well as CA 19-9 kinetics during systemic chemotherapy can provide prognostic information regarding survival of patients with metastatic PC...
  13. ncbi Application of a time-varying covariate model to the analysis of CA 19-9 as serum biomarker in patients with advanced pancreatic cancer
    Stefan Boeck
    Department of Internal Medicine III, Ludwig Maximilians University of Munich, Munich, Germany
    Clin Cancer Res 16:986-94. 2010
    ..The clinical relevance of CA 19-9 as surrogate biomarker in advanced pancreatic cancer is a matter of debate...
  14. ncbi Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer
    Stefan Boeck
    Department ofInternal Medicine III, Klinikum Grosshadern, Ludwig Maximilians University of Munich, Munich, Germany
    Oncology 73:221-7. 2007
    ..Oral capecitabine (Cap) has shown promising activity in first-line chemotherapy trials in PC patients...
  15. ncbi Prognostic relevance of CA 19-9, CEA, CRP, and LDH kinetics in patients treated with palliative second-line therapy for advanced pancreatic cancer
    Michael Haas
    Department of Internal Medicine III, Klinikum Grosshadern, Ludwig Maximilians University of Munich, Marchioninistr 15, 81377 Munich, Germany
    Tumour Biol 31:351-7. 2010
    ..86, p = 0.001) and CRP (HR 3.20, p = 0.001). Serum biomarker kinetics might serve as useful prognostic tools during second-line chemotherapy in advanced pancreatic cancer...
  16. ncbi Current oncological treatment of patients with pancreatic cancer in germany: results from a national survey on behalf of the Arbeitsgemeinschaft Internistische Onkologie and the Chirurgische Arbeitsgemeinschaft Onkologie of the Germany Cancer Society
    Stefan Boeck
    Department of Internal Medicine III, Klinikum Grosshadern, Ludwig Maximilians University of Munich, Munich, Germany
    Oncology 77:40-8. 2009
    ..No data have previously been available regarding the current treatment of patients with pancreatic cancer (PC) in German hospitals and medical practices...
  17. ncbi Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer
    V Heinemann
    Department of Internal Medicine III and Comprehensive Cancer Center, Klinikum Grosshadern, Ludwig Maximilians University of Munich, Marchioninistr 15, D 81377 Munich, Germany
    Br J Cancer 108:766-70. 2013
    ..Conclusion:In this proof-of-concept study targeting the uPA system in LAPC, the addition of upamostat to gemcitabine was tolerated well; similar survival results were observed for the three treatment arms...
  18. ncbi The influence of KRAS and BRAF mutations on the efficacy of cetuximab-based first-line therapy of metastatic colorectal cancer: an analysis of the AIO KRK-0104-trial
    D P Modest
    Department of Medicine III, University of Munich, Munich, Germany
    Int J Cancer 131:980-6. 2012
    ....
  19. ncbi Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer
    S Boeck
    Medizinische Klinik und Poliklinik III, Klinikum Grosshadern, Ludwig Maximilians Universitat Munchen, Germany
    Ann Oncol 19:340-7. 2008
    ..To compare the efficacy and safety of three different chemotherapy doublets in the treatment of advanced pancreatic cancer (PC)...
  20. ncbi Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the 'Arbeitsgemeinschaft Internistische Onkologie'
    Stefan Boeck
    Department of Internal Medicine III, Klinikum Grosshadern, Ludwig Maximilians University of Munich, Germany
    Anticancer Drugs 21:94-100. 2010
    ..12%), and hand-foot syndrome (7 vs. 0%). No treatment-related death was observed. In conclusion, this interim safety analysis suggests that treatment with erlotinib 150 mg/day is feasible in combination with capecitabine or gemcitabine...
  21. ncbi Second-line chemotherapy with pemetrexed after gemcitabine failure in patients with advanced pancreatic cancer: a multicenter phase II trial
    S Boeck
    Department of Internal Medicine III, University Hospital Grosshadern, Ludwigs Maximilians University, Marchioninistrasse 15, D 81377 Munich, Germany
    Ann Oncol 18:745-51. 2007
    ..A standard second-line chemotherapy regimen has yet to be defined for patients with gemcitabine (Gem)-refractory advanced pancreatic cancer (PC)...
  22. ncbi Risk factors for surgical complications in distal pancreatectomy
    Hendrik Seeliger
    Department of Surgery, Munich University Medical Center, Germany
    Am J Surg 200:311-7. 2010
    ..Pancreatic fistula (PF) represents a major complication after distal pancreatectomy. In a consecutive series of 110 patients, risk factors for the incidence of PF and surgical morbidity were identified...
  23. ncbi [Importance of neoadjuvant chemotherapy in gastrointestinal tumors. A new standard?]
    Nicolas Moosmann
    Medizinische Klinik III, Universitätsklinikum München Grosshadern, Marchioninistrasse 15, 81377 Munchen
    Med Klin (Munich) 102:551-62; quiz 563-4. 2007
  24. ncbi Perioperative management of pancreatic cancer
    V Heinemann
    Department of Medical Oncology, Klinikum Grosshadern, University of Munich, Munich, Germany
    Ann Oncol 19:vii273-8. 2008
  25. ncbi Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR
    Volker Heinemann
    Department of Hematology Oncology, Klinikum Grosshadern, Ludwig Maximilians University of Munich, Marchionini Street 15, 81377 Munich, Germany
    Cancer Treat Rev 35:262-71. 2009
    ..While molecular parameters help to predict treatment efficacy upfront, skin toxicity has been accepted as an independent predictor of response during exposure to anti-EGFR therapy...
  26. ncbi The role of adjuvant chemotherapy for patients with resected pancreatic cancer: systematic review of randomized controlled trials and meta-analysis
    Stefan Boeck
    Department of Internal Medicine III, Klinikum Grosshadern, Munich, Germany
    Oncology 72:314-21. 2007
    ..The role of adjuvant treatment strategies (including chemotherapy and chemoradiotherapy) following resection of pancreatic cancer remains controversial...
  27. ncbi UGT1A1 gene polymorphism: impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorectal cancer
    Christoph Schulz
    Department of Haematology and Oncology, Ludwig Maximilians University of Munich, Campus Grosshadern, Marchioninistr 15, Munich 81377, Germany
    World J Gastroenterol 15:5058-66. 2009
    ....
  28. ncbi Importance of performance status for treatment outcome in advanced pancreatic cancer
    Stefan Boeck
    Department of Internal Medicine III, Klinikum Grosshadern, Ludwig Maximilians University of Munich, Marchioninistrasse 15, Munich 81377, Germany
    World J Gastroenterol 13:224-7. 2007
    ..By contrast, patients with a poor performance status (KPS < or = 80%) have no advantage from intensified therapy and should rather receive single-agent treatment...
  29. ncbi UGT1A1 genotyping: a predictor of irinotecan-associated side effects and drug efficacy?
    Christoph Schulz
    Department of Haematology, Ludwig Maximilians University of Munich, Campus Grosshadern, Munich, Germany
    Anticancer Drugs 20:867-79. 2009
    ....
  30. ncbi RP101 improves the efficacy of chemotherapy in pancreas carcinoma cell lines and pancreatic cancer patients
    Rudolf Fahrig
    RESprotect, Dresden Germany
    Anticancer Drugs 17:1045-56. 2006
    ..The data indicate that acquisition of chemoresistance was prevented and the antitumor efficacy of standard chemotherapy was improved. To our knowledge, RP101 co-treatment is more efficient than any other regimen published...
  31. ncbi Hemolytic-uremic syndrome associated with gemcitabine treatment for metastatic pancreatic cancer
    Stefan Boeck
    J Clin Gastroenterol 42:551-2. 2008
  32. ncbi Second-line therapy in gemcitabine-pretreated patients with advanced pancreatic cancer
    Stefan Boeck
    J Clin Oncol 26:1178-9; author reply 1179. 2008
  33. ncbi Peripheral dendritic cell chimerism in allogeneic hematopoietic stem cell recipients
    Markus Pihusch
    Abteilung fuer Haematologie und Internistische Onkologie, Klinikum der Universitaet Regensburg, Regensburg, Germany
    Transplantation 80:843-9. 2005
    ..Although leukocyte and T-cell chimerism analyses are performed routinely suggesting a predictive value on the patients outcome, little is known about chimerism of dendritic cells (DC) representing strong initiators of immune responses...